Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (Prognostic Index for Nailfold Capillaroscopic Examination)

Arthritis and Rheumatism

Volumn 58, Issue 7, 2008, Pages 2174-2182

  Ingegnoli, Francesca ^a   Boracchi, Patrizia ^a   Gualtierotti, Roberta ^a   Lubatti, Chiara ^a   Meani, Laura ^a   Zahalkova, Lenka ^a   Zeni, Silvana ^a   Fantini, Flavio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALGORITHM; ARTICLE; BLEEDING; CAPILLAROSCOPY; CAPILLARY; CLINICAL PRACTICE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAILFOLD CAPILLAROSCOPY; PRIORITY JOURNAL; PROGNOSIS; RAYNAUD PHENOMENON; REGRESSION ANALYSIS; SCLERODERMA; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MICROSCOPIC ANGIOSCOPY; MIDDLE AGED; NAILS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RAYNAUD DISEASE; RISK ASSESSMENT; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 47249092325     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23555     Document Type: Article

References (31)

1. Wigley FM. Clinical practice: Raynaud's phenomenon [review]. N Engl J Med 2002;347:1001-8.
2. Block JA, Sequeira W. Raynaud's phenomenon [review]. Lancet 2001;357:2042-8.
3. Suter LG, Murabito JM, Felson DT, Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 2005;52:1259-63.
4. Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Franco A, Drouet P, et al. Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol 1993;20:70-6.
5. Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Palesch Y, Biro C, et al. Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. J Rheumatol 1997;24:879-89.
6. De Angelis R, Salaffi F, Grassi W. Raynaud's phenomenon: prevalence in an Italian population sample. Clin Rheumatol 2006;25:506-10.
7. Fraenkel L. Raynaud's phenomenon: epidemiology and risk factors. Curr Rheumatol Rep 2002;4:123-8.
8. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998;158:595-600.
9. LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992;10:485-8.
10. Harper FE, Maricq HR, Turner RE, Lidman RW, Leroy EC. A prospective study of Raynaud phenomenon and early connective tissue disease: a five-year report. Am J Med 1982;72:883-8.
11. Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G. The evolution of Raynaud's phenomenon: a longterm prospective study. J Rheumatol 1995;22:2226-32.
12. Priollet P, Vayssairat M, Housset E. How to classify Raynaud's phenomenon: long-term follow-up study of 73 cases. Am J Med 1987;83:494-8.
13. Fitzgerald O, Hess EV, O'Connor GT, Spencer-Green G. Prospective study of the evolution of Raynaud's phenomenon. Am J Med 1988;84:718-26.
14. Kallenberg CG. Early detection of connective tissue disease in patients with Raynaud's phenomenon. Rheum Dis Clin North Am 1990;16:11-30.
15. Maricq HR, Harper FE, Khan MM, Tan EM, LeRoy EC. Microvascular abnormalities as possible predictors of disease subsets in Raynaud's phenomenon and early connective tissue disease. Clin Exp Rheumatol 1983;1:195-220.
16. Maricq HR, Spencer-Green G, LeRoy EC. Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med 1976;61:862-70.
17. Maricq HR, LeRoy EC, Angelo WA, Medsger TA Jr, Rodnan GP, Sharp GC, et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 1980;23:183-9.
18. Cutolo M, Pizzorni C, Tuccio M, Burroni A, Craviotto C, Basso M, et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) 2004;43:719-26.
19. Zufferey P, Depairon M, Chamot AM, Monti M. Prognostic significance of nailfold capillary microscopy in patients with Raynaud's phenomenon and scleroderma-pattern abnormalities: a six-year follow-up study. Clin Rheumatol 1992;11:536-41.
20. Jouanny P, Schmidt C, Feldmann L, Schmitt J. Peri-ungual capillaroscopy: value in the diagnosis of systemic diseases. Presse Med 1993;22:1256-60. In French.
21. Houtman PM, Kallenberg CG, Fidler V, Wouda AA. Diagnostic significance of nailfold capillary patterns in patients with Raynaud's phenomenon: an analysis of patterns discriminating patients with and without connective tissue disease. J Rheumatol 1986;13:556-63.
22. Maricq HR, Weiberger AB, LeRoy EC. Early detection of scleroderma spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud phenomenon. J Rheumatol 1982;9:289-91.
23. Blockmans D, Beyens G, Verhaeghe R. Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases. Clin Rheumatol 1996;15:148-53.
24. Meli M, Gitzelmann G, Koppensteiner R, Amann-Vesti BR. Predictive value of nailfold capillaroscopy in patients with Raynaud's phenomenon. Clin Rheumatol 2006;25:153-8.
25. Kenik JG, Maricq HR, Bole GG. Blind evaluation of the diagnostic specificity of nailfold capillary microscopy in the connective tissue diseases. Arthritis Rheum 1981;24:885-91.
26. Cutolo M, Grassi W, Matucci Cerinic M. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 2003;48:3023-30.
27. Maricq HR, Valter I. A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 2004;22:S5-13.
28. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
29. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
30. Ingegnoli F, Gualtierotti R, Lubatti C, Zahalkova L, Meani L, Boracchi P, et al. Feasibility of different capillaroscopic measures for identifying nailfold microvascular alterations. Semin Arthritis Rheum 2007. E-pub ahead of print.
31. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.